My Forecasts
Oncology portfolio across brands, geographies and forecast cycles
Active Brands
3
Total Forecast Cycles
12
Pending Reviews
3
Active Scenarios
28
| Brand | Indication | Description | Tumor Area | Geography | Forecast Cycle | Status | Last Updated | Owner | Actions |
|---|---|---|---|---|---|---|---|---|---|
| etentamig-(ABBV-383) | Multiple Myeloma | NCT06158841 - Phase 3 CERVINO study | Hematology (Myeloma) | US | US Forecast 2028 | Active | 2026-10-14 | John | |
| Temab-A (ABBV-400) | Colorectal Cancer | Illustrative planning forecast — confirm study details | Solid Tumors | US | US Forecast 2028 | Draft | 2026-10-22 | John | |
| Temab-A(ABBV-400) | Non small lung cancer | Illustrative planning forecast — confirm study details | Solid Tumors | EU5 | EU5 Forecast 2028 | In Review | 2026-10-22 | John |